Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-10-28 (biospace.com)
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining concerned about confirmatory trials and clinical efficacy, especially as products greenlit under this pathway are pulled from the market.
Read more
2024-10-14 (biospace.com)
5 Accelerated Approvals Gone Wrong
Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market. However, recent years have seen a number of high-profile market withdrawals and failed confirmatory trials.
Read more
2024-01-16 (pharmamanufacturing.com)
Bayer sells stroke asset to JiXing
Fresh off a $162 million series D funding round, the Chinese biotech strikes a deal for a phase 2 plasminogen activator
Read more
2023-08-09 (endpts.com)
Denali, Takeda scrap PhI Alzheimer's drug due to safety signals, 'rapidly evolving' landscape
As Biogen takes a preclinical Denali compound targeting amyloid beta forward in Alzheimer’s, Denali is shelving another Alzheimer’s candidate that is partnered with Takeda and hits a different target.
Read more
2022-09-27 (masslive.com)
Biogen pays $900M to settle allegations it paid kickbacks to doctors to prescribe MS drugs
The Cambridge, Massachusetts-based pharmaceutical company in a statement said it settled so it can focus on “our patients and strategic priorities” and said the settlement does not include an admission of liability.
Read more
2010-02-15 (genengnews.com)
Trends in Monoclonal Antibody Production
Quality by design approach strives for greater process control and product quality.
Read more